Clinical Trials | December 12, 2025
Neurizon’s ALS drug regimen cleared for launch in Healey platform trial
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
The companies aim to expand treatment options for millions living with metabolic disorders
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
While Merck can appeal, Halozyme said it expects the order to hold
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
It's an acquisition that aims at forming one of the US's largest oncology trial networks
Subscribe To Our Newsletter & Stay Updated
